Developing new treatments for COVID-19
Official title: Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
Funded at Fox Chase Chemical Diversity Center, INC · NIH-10688262 · Data updated 2026-11-12
This study is working on new medicines that can help fight COVID-19 by blocking the virus from spreading in the body, which could lead to better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fox Chase Chemical Diversity Center, INC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | August 22, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $292,428 |
| NIH project number | 5R41AI172464-02 |
| Project ID | NIH-10688262 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of severe COVID-19 infection or those who have tested positive for SARS-CoV-2.
✕Less likely to help
Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not benefit from this research.
What this research studies
This research focuses on creating small molecule compounds that target the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. The approach involves understanding how the virus interacts with specific host proteins to facilitate its spread and developing antiviral agents that can disrupt these interactions. By targeting these mechanisms, the research aims to provide effective treatments against SARS-CoV-2 and its emerging variants. Patients may benefit from new antiviral therapies that could reduce the severity of COVID-19 infections.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral treatments that significantly improve outcomes for patients infected with COVID-19.
How similar studies have gone: Other research has shown promise in developing antiviral agents targeting similar mechanisms in viral infections, indicating a potential for success in this novel approach.
Where this research is happening
-
Fox Chase Chemical Diversity Center, INC
Doylestown, United States Active
Researchers
- Principal investigator: Harty, Ronald N — Fox Chase Chemical Diversity Center, INC
- Study coordinator: Harty, Ronald N
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.